FDA OKs Isis Orphan Drug Amid Shareholder's Safety Suit

Law360, New York (January 30, 2013, 7:47 PM EST) -- The Food and Drug Administration announced Tuesday that it approved Kynamro as an orphan drug treatment for a rare type of high cholesterol, a drug whose safety concerns prompted a shareholder suit last month against Isis Pharmaceuticals Inc.

Along with Genzyme, a unit of Sanofi, Isis developed Kynamro, a mipomersen sodium injection, to treat an inherited cholesterol disorder called homozygous familial hypercholesterolemia. The FDA said in its announcement that the drug, used in addition to lipid-lowering medications and diet, will help reduce so-called bad cholesterol in...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.